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tpidemiology, health services research, and outcomes re-
earch have commanded a growing presence in the medical
iterature and have had an increasing impact on practice and
olicy. Summarizing the important contributions in this
iterature requires a review of a broad spectrum of sources
nd investigators, because the highest-impact work typically
esults from multidisciplinary collaboration. This overview
ighlights findings from prominent epidemiology, health
ervices research, and outcomes research publications from
pril 2005 through March 2006. Although the limited
pace of this review does not permit inclusion of every
igh-quality publication in this area, we have highlighted
epresentative work of particular interest or relevance con-
istent with the core domains of health care, as articulated
y the National Academy of Sciences Institute of Medi-
ine—safety, effectiveness, equity, efficiency, timeliness, and
atient-centeredness. Additional categories for quality and
pidemiology are also included.
AFETY
wo prominent articles addressed the issue of incorrect
edication dosing. Mehta et al. (1) found that approxi-
ately 5% of the subjects in the ASSENT-2 (Assessment of
he Safety and Efficacy of a New Thrombolytic-2) trial
eceived the incorrect dose of fibrinolytic agent. Because this
ccurred within the context of a randomized trial, it likely
nderestimates rates of incorrect dosing in practice. Older
atients, women, black patients, those with low body weight
nd systolic blood pressure, and those with a higher Killip
lass had a higher risk for incorrect dosing. Overdose and
nderdose were associated with higher mortality, not only
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ccepted September 7, 2006.or the fibrinolytic agent but also for placebo, indicating that
aseline patient characteristics and/or concomitant deficien-
ies in quality of care likely played a role in these differences.
lexander et al. (2), assessing the dosing of antiplatelet and
ntithrombin agents for ST-segment elevation myocardial
nfarction (STEMI), found that 42% of patients received at
east 1 dose of antithrombotic agents that was higher than
ecommended. This mistake was particularly common with
lycoprotein IIb/IIIa inhibitors (27%) and unfractionated
eparin (33%). Again, older age, female gender, and low
ody weight, along with renal insufficiency, diabetes, and
eart failure, were risk factors for inappropriate medication
osing. Excess dosing was associated with greater risks of
leeding and death.
Meta-analyses also examined safety issues associated with
hronic anticoagulation. In a meta-analysis of 10 random-
zed trials, Rothberg et al. (3) reported that the use of
arfarin plus aspirin after an acute myocardial infarction
AMI) was associated with a 250% increase in the risk of
leeding compared with aspirin alone. It was also associated
ith a 44% reduction in the risk of a subsequent AMI, a
4% reduction in stroke, and a 20% reduction in revascu-
arization procedures, findings that indicate a need for safer
pproaches to anticoagulation therapy. This topic was ad-
ressed by Heneghan et al. (4) in a meta-analysis of
elf-monitoring of oral anticoagulation. In 14 trials, they
ound that self-monitoring was associated with a 55%
eduction in the odds of thromboembolic events, a 39%
eduction in mortality, and a 35% reduction in major
leeding. The combination of self-monitoring and self-
djustment showed even more impressive reductions in
hromboembolic events and mortality, but not in major
leeding.
Several studies addressed the safety of statins, including
osuvastatin, the newest high-potency agent. In a postmar-
eting analysis, Alsheikh-Ali et al. (5) reviewed statin-
ssociated events reported to the Food and Drug Adminis-
ration during rosuvastatin’s first year of approval. The
dverse event reports per million (composite of event reports
ccurring at moderate doses of rosuvastatin for rhabdomy-
lysis, proteinuria, nephropathy, or renal failure) were
igher for rosuvastatin than for atorvastatin, simvastatin, or
ravastatin. Interestingly, the adverse events for rosuvastatin
ended to be reported earlier after the initiation of therapy.
The possible risks of cancer from statins were also
nvestigated. In a meta-analysis of 26 studies, Dale et al. (6)
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r mortality. In a prospective meta-analysis using individual
ata for 90,056 subjects in 14 trials, the Cholesterol Treat-
ent Trialists’ Collaborators also concluded that there was
o evidence showing that statins increased the risk of all
ancer or site-specific malignancies (7). In a case-control
tudy, Poynter et al. (8) found that statins may reduce the
isk of colorectal cancer, although these findings should be
onsidered hypothesis-generating because of the study de-
ign.
Concerns that angiotensin receptor blockers might in-
rease risk for an AMI were refuted by 2 articles. McDonald
t al. (9), in a systematic review of 19 trials including 31,569
atients, found no strong evidence of a hazard with angio-
ensin receptor blockers. In an analysis of the CHARM
Candesartan in Heart failure: Assessment of Reduction in
ortality and morbidity) studies, Demers et al. (10) re-
orted a reduction in AMI risk in patients with heart failure
reated with candesartan.
Several other articles with strong safety implications in
linical practice were noteworthy. Masoudi et al. (11)
eported dramatic increases in the use of spironolactone in
atients with heart failure at high risk for hyperkalemia after
he publication of RALES (Randomized Aldactone Evalu-
tion Study). In a prospective, observational study, Iakovou
t al. (12) reported a 1.3% 9-month rate of acute stent
hrombosis after drug-eluting stent (DES) placement, more
requent than rates reported in randomized trials. An
mportant risk factor was premature discontinuation of
ntiplatelet therapy. Mangano et al. (13), in an observa-
ional study, reported that aprotinin in patients undergoing
ardiac surgery was associated with double the risk of renal
ailure.
FFECTIVENESS
ystematic reviews investigated issues of treatment effec-
iveness that individual studies have been unable to address.
n an important systematic review, Katritsis and Ioannidis
14) compared percutaneous coronary intervention (PCI)
ith medical therapy in patients with stable angina. They
ound that PCI did not reduce the risk of death, AMI, or
he need for subsequent revascularization.
Many other reviews were notable. A meta-analysis of 22
tudies of perioperative beta-blockade for noncardiovascular
urgery found only a nominally significant reduction in the
isk of the composite of cardiovascular mortality, nonfatal
MI, and nonfatal cardiac arrest while conferring a signif-
cantly higher risk of bradycardia or hypotension requiring
herapy, raising questions about the widespread use of
eta-blockade around the time of noncardiovascular surgery
15). A comparison of studies of routine invasive strategy
ompared with a selective invasive strategy for acute coro-
ary syndromes (ACS) found that the routine invasive
pproach reduced the risk of AMI, severe angina, and
ehospitalization, but was associated with an early hazard of (eath and a longer-term trend toward a mortality reduction
16). In a study of acute reperfusion strategies for STEMI,
eeley et al. (17) compared standard PCI with facilitated
CI (i.e., administration of a medication before planned
mmediate PCI to improve preprocedural coronary pa-
ency). They found that despite higher rates of early TIMI
Thrombolysis in Myocardial Infarction)-3 flow in the
nfarct vessel, the facilitated strategy resulted in a higher risk
f death, nonfatal reinfarction, urgent target vessel revascu-
arization, and major bleeding. The investigators concluded
hat facilitated PCI should not be used outside of random-
zed trials. In a meta-analysis of first-line antihypertensive
herapy, Lindholm et al. (18) found that beta-blockers were
ssociated with a 16% higher risk of stroke compared with
ther active agents and conferred less of a benefit on stroke
han would be expected based on other antihypertensive
rials. The investigators suggest that beta-blockers should be
onsidered inferior—and thus inappropriate—comparators
or future hypertension trials.
The relationship between procedural volume and out-
omes was the focus of several studies. In a study of PCI in
he stent era in New York, Hannan et al. (19) found that
ower hospital (at least 400 cases annually as a cut point) and
perator (at least 75 cases annually) volumes were important
orrelates of worse in-hospital outcomes, including mortal-
ty (for hospital volume), and same-day bypass surgery (for
oth hospital and operator volume). In a national study of
edicare patients, Schelbert et al. (20) found that institu-
ional volume of valve replacement procedures was associ-
ted with the use of bioprosthetic valves for older patients,
n approach consistent with recent guidelines. Al-Khatib et
l. (21) reported that physician procedure volumes for
mplantable cardioverter-defibrillator (ICD) placement
ere related to outcomes. A physician volume threshold
elow 11 implants annually was associated with significantly
igher risks of mechanical complications, and a threshold
elow 18 was associated with higher risks of device infec-
ion. These results have potential implications for compe-
ency statements and policy, although substantial variations
n the relationship between volume and outcomes suggest
hat volume criteria alone are inadequate barometers, and
ay still misclassify physicians and institutions when used
s a surrogate for direct measurement of quality.
In a post-hoc analysis of CHARM, Granger et al. (22)
ound that adherence to medications was associated with
etter outcomes even among placebo-treated subjects. The
mplication is that behaviors associated with adherence have
mportant effects on prognosis, and raise questions about the
pecific mediators of this effect.
An examination of RITA-3 (Randomised Intervention
rial of Unstable Angina-3) shows the importance of
nderstanding the time horizon in testing the value of
reatments (23). Among patients with non-STEMI ran-
omized to an intervention strategy (routine angiography
ollowed by revascularization) or a conservative strategy
ischemia-driven or symptom-driven angiography), rates of
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The Year in Epidemiology, Health Services Research, and Outcomes Research November 7, 2006:1886–95eath and nonfatal AMI were similar at 1 year, but were
ower in the routine angiography group by 5 years of
ollow-up (16.6% vs. 20.0%). Although the 1-year results
ay have limited enthusiasm for an early invasive strategy,
he longer-term results will likely increase support for an
arly invasive strategy for ACS.
Another study raised questions about a controversial
ntervention in critical care. The ESCAPE (Evaluation
tudy of Congestive Heart Failure and Pulmonary Artery
atheterization Effectiveness) trial investigators found that
he use of pulmonary artery catheterization to guide therapy
or patients hospitalized with severe heart failure did not
mprove outcomes but resulted in more adverse events (24).
Three trials found major benefits from relatively straight-
orward interventions in care delivery. In a study of 1,518
utpatients with heart failure, investigators from Argentina
eported lower risks of death or admission for heart failure
nd better quality of life with a simple telephone interven-
ion to provide education, counseling, and monitoring (25).
arnfather et al. (26) reported a 17% improvement in
moking quit rates with a 10-min point-of-care test for
alivary nicotine metabolites. An unrestricted visiting policy
n the intensive care unit reduced cardiovascular complica-
ions and patient complications without an increased risk of
ajor infection (27).
The international PRESTO (Prevention of Restenosis
ith Tranilast and its Outcomes) trial provided an oppor-
unity to assess differences in the effectiveness of PCI across
ountries. Patients in the U.S. had higher rates of target
essel revascularization (18% vs. 11%) and angiographic
estenosis (65% vs. 48%) than in other countries, differences
ot entirely accounted for by the higher risk profile of U.S.
atients (28). The finding suggests that issues beyond
atient selection, such as procedural techniques, may explain
hese differences.
QUITY
he assessment of health differences and disparities in
reatment and outcomes of cardiovascular diseases by race,
ender, and socioeconomic status remains an active area of
nvestigation. In an observational study of patients with
CS, Spertus et al. (29) found that black patients had a
igher prevalence of angina, worse quality of life, and worse
hysical function than white patients 1 year after their
vent, although the underlying explanations for this finding
emain unclear. Two studies investigated temporal trends in
ace and gender differences in cardiovascular care. Among
edicare beneficiaries from 1992 through 2001, Jha et al.
30) found that differences in procedure use by race persisted
hrough the decade. Vaccarino et al. (31) found that rates of
eperfusion therapy and procedures varied according to race
nd gender, and the differences did not change from 1994
hrough 2002. They also noted that in-hospital mortality
as significantly higher for black women than for white
omen or for all men. pA central insight this year expanded on race differences in
reatment and outcomes among hospitals and regions.
kinner et al. (32) found that black patients with an AMI
ay have worse outcomes because they are more commonly
dmitted to hospitals with higher mortality rates. Barnato et
l. (33) also showed that race differences in treatment for
atients with AMI were largely explained by the hospitals to
hich the patients were admitted. Lucas et al. (34) deter-
ined that higher crude mortality rates among black pa-
ients for 4 cardiovascular surgical procedures were not
ubstantially changed after adjustment for patient-level
haracteristics, but were no longer present after accounting
or hospital factors. These 3 studies suggest that racial
isparities might be most effectively addressed by interven-
ions directed at the performance of hospitals that dispro-
ortionately serve this population. In addition to the accu-
ulating evidence of the role of the hospital in differences
nd disparities in care, Rathore et al. (35) identified sub-
tantial national variation in racial differences by geographic
egion, with the greatest variation in the South.
Data from NHANES (National Health and Nutrition
xamination Survey) provided insights into racial disparities
n the prevalence and management of high blood pressure.
ertz et al. (36) found that the prevalence of hypertension
ncreased in black subjects from 35.8% in 1988 to 1994 to
1.4% in 1999 to 2002. Rates for white subjects also
ncreased, but were only 28.1% in the latter period. Black
ubjects were much less likely than white subjects to have
ad their blood pressure controlled (51% of black subjects
s. 40% of white subjects).
A few important studies assessed differences in care and
utcomes by socioeconomic status. Investigators from the
orcester Heart Attack Study showed that patients living
n high-poverty areas had a 30% greater risk of dying
ompared with those in the wealthiest areas (37). Shisheh-
or et al. (38) determined that impaired functional capacity
nd abnormal heart rate were more common in patients
ith low socioeconomic status, and these abnormal re-
ponses explained a major proportion of the association
etween socioeconomic status and mortality. In a Canadian
bservational study of patients with AMI, Alter et al. (39)
howed that the excess mortality risk associated with low
ocioeconomic status was largely explained by risk factors
resent at the time of the event.
Spertus et al. (40) found that the benefit of clinical
evascularization strategies varied depending on the pa-
ient’s ability to afford health care, showing that those who
ad difficulty paying for health care had better outcomes
ith surgical revascularization. This study leads to the
ncomfortable conclusion that the financial burden of
ealth care might affect the benefit of particular strategies.
Gender differences in angina treatment also received
ome attention. Hemingway et al. (41) reported in a
rospective cohort study that the age-standardized annual
ncidence of angina (based on treatment with nitrates or a
ositive invasive or noninvasive test result) was similar in
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hat women with stable angina were less likely than men to
e referred for stress tests or coronary angiography or to be
reated with antiplatelet and statin therapy. Women with
onfirmed coronary disease were also twice as likely to die or
ave a nonfatal AMI in the 1 year of follow-up.
OSTS
piraling health care costs are directing more attention
oward the economics of health care. A recent report from
he Centers for Medicare and Medicaid Services found that
ealth spending in the U.S. increased by 7.9% to $1.9
rillion in 2004 (43). This amount translates to $6,280 per
erson and 16% of the gross domestic product. The increase
n spending slowed in 2004, with the percent of gross
omestic product increasing only by 0.1%, mostly as a result
f above-average economic growth.
Contributing to rapidly rising costs, the use of cardiovas-
ular diagnostic tests and treatments proliferated rapidly in
he U.S. and Canada. In the U.S., imaging stress testing
ncreased nearly 3-fold between 1993 and 2001 to a rate of
2 tests per 1,000, without contemporaneous declines in the
ate of nonimaging stress tests (44). Rates of PCI doubled
nd rates of bypass surgery remained relatively stable. In
anada, where financial incentives to perform tests and
rocedures are less pronounced, the use of diagnostic tests
nd reperfusion therapy still increased significantly between
992 and 2001, with annual increases of 6% for echocardi-
graphy, 7% for perfusion stress testing, 12% for PCI, and
% for bypass surgery (45).
Expensive interventions with demonstrated efficacy, such
s ICDs, are a natural focus for economic analyses. Sanders
t al. (46) assessed the cost-effectiveness of ICD in primary
revention studies that enrolled patients with left ventricular
ystolic dysfunction but without a history of life-threatening
entricular arrhythmias. In this analysis, ICD therapy had a
ost-effectiveness range of $34,000 to $70,200 per quality-
djusted life-year (QALY) gained. Goldberger et al. (47)
nvestigated 3 approaches to ICD therapy among patients
ithout a clear indication for a dual-chamber device: uni-
ersal single-chamber ICD implantation with subsequent
pgrade as indicated, universal dual-chamber device im-
lantation, and device selection determined by electrophys-
ological testing. The strategy of universal dual-chamber
CD implantation was least costly as long as the need for
pgrades exceeded 10%.
In a study of in-home automated defibrillators, Cram et
l. (48) found that for adults older than 60 years with an
nnual probability of sudden death 4% (e.g., patients with
rior AMI but without left ventricular systolic dysfunction),
he estimated cost-effectiveness of automated external defi-
rillators exceeds $100,000 per QALY and should be
onsidered relatively expensive. Among those with 6%
nnual sudden death rates (e.g., those with ischemic cardio- ayopathy), the incremental cost-effectiveness was $88,000
er QALY (48).
Resynchronization therapy is another effective but expen-
ive strategy for treating patients with symptomatic heart
ailure caused by left ventricular systolic dysfunction. Feld-
an et al. (49) evaluated the cost effectiveness of this
trategy among patients in the COMPANION (Compari-
on of Medical, Pacing, and Defibrillation Therapies in
eart Failure) trial. Cardiac resynchronization therapy re-
uced the risk of death and hospitalization in patients with
eft ventricular systolic dysfunction, advanced symptoms
New York Heart Association functional class III or IV),
nd intraventricular conduction delays. Hospital costs were
educed by 29% for those who received resynchronization
ia a pacemaker-defibrillator and by 37% for those who
eceived therapy via a pacemaker compared with those
eceiving optimal pharmacological therapy alone. The cost
ffectiveness ratio was $50,000 per QALY for either
esynchronization strategy approach.
Among other cost effectiveness analyses, one focusing on
tents was notable. Kaiser et al. (50) assessed the economic
ttractiveness of DES in a real-world setting. They found
hat although the DES strategy reduced the need for target
esion revascularization, it was associated with a substantial
ncremental cost per QALY of $67,015 to $90,036. How-
ver, in subgroups with relatively high restenosis risks, such
s high-risk elderly patients with 3-vessel disease, those with
ultiple lesions, long lesions, or small vessels, the strategy
as more cost-effective or even cost-saving. In another
ost-effectiveness analysis in a community-based popula-
ion, Bagust et al. (51) found that even when restricting the
umber of DES per patient, only a small minority (4%) of
ES were economically attractive, and that 90% rates of
ubstitution of DES for bare-metal stents, the current U.S.
ractice, could only be justified with modest price premiums
or DES ($212 for sirolimus-eluting and $167 for
aclitaxel-eluting stents).
UALITY
everal important articles addressed quality of care. Alex-
nder et al. (52) found that older patients with ACS were
ess likely to be treated with early aspirin and beta-blockers
han younger patients. Interestingly, above age 65 there was
ot a substantial increase in underuse. Ko et al. (53)
ompared the quality of heart failure care and mortality
etween the U.S. and Ontario, Canada. Patients in both
ountries received similar treatment as measured by quality
ndicators, but those in the U.S. had a lower adjusted risk of
ortality within the first 30 days after hospitalization. By 1
ear after discharge, however, the survival difference disap-
eared. The convergence in longer-term mortality may
esult from differences in the quality of outpatient follow-
p, but the study was not able to test this hypothesis.
Historically, the preponderance of studies of guidelinedherence has been cross-sectional. Newby et al. (54)
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ions after hospital discharge in patients with coronary
rtery disease, finding that their subsequent medication use
as often inconsistent and many failed to continue
vidence-based therapy over time. Watkins et al. (55)
xamined trends in mortality and treatment between 1987
nd 2000 in the ARIC (Atherosclerosis Risk in Commu-
ities) study. They found a marked improvement in 30-day
ortality and associated improvements in treatment, sug-
esting a meaningful relationship between measures of care
uality and health outcomes.
Appropriate calibration of the intensity of therapy with
atient risk remains an issue of significant concern, high-
ighted by Lee et al. (56) in a study of evidence-based heart
ailure therapy according to baseline mortality risk. The
ikelihood of prescribing angiotensin-converting enzyme
nhibitors and beta-blockers was inversely related to pa-
ients’ risk of dying, even though the highest-risk patients
ould derive the greatest treatment benefit. The means of
mproving the alignment between treatment intensity and
atient risk remains an important area of investigation.
Beyond descriptions of patterns of care, studies of the
mplementation of quality improvement interventions are
ccurring with greater frequency. Moscucci et al. (57) found
hat a regional quality improvement initiative in Michigan
mproved processes and outcomes for patients undergoing
CI. Zhang et al. (58) evaluated the effect of data feedback
nd clinical process improvement in 38 hospitals, reporting
ignificant improvements in AMI process measures after
mplementation. Investigators for the NC ACE (North
arolina Achieving Cardiac Excellence) project reported
mprovements in angiotensin-converting enzyme inhibitor
nd beta-blocker use for patients with heart failure enrolled
n managed care Medicaid and Medicare (59). Butler et al.
60) reported improved inpatient heart failure care after the
nstitution of a computerized physician order entry system.
Not all such studies were positive, however. Australian
nvestigators, in a cluster-randomized trial, found that
uch-heralded medical emergency teams, which respond to
nstable patients before they progress to an arrest, did not
educe the risk of the combined end point of cardiac arrest,
nexpected death, or unplanned intensive care unit admis-
ion (61). Beck et al. (62) found that a one-time hospital
eport card for AMI patients was ineffective in improving
are. These negative results highlight the importance of
ubjecting quality improvement interventions to the rigors
f clinical study to prove (or disprove) their impact.
Several studies specifically addressed factors associated
ith acute reperfusion time for STEMI. McNamara et al.
63) showed that there has been little recent improvement in
ime-to-reperfusion nationwide. Nallamothu et al. (64)
mphasized the particularly long times for patients who are
ransferred from one institution to another for primary PCI.
agid et al. (65) reported that the time of day and day of
he week were related to door-to-balloon times but not
oor-to-drug times. Curtis et al. (66) showed that prehos- 6ital electrocardiography was associated with much faster
imes. Finally, Bradley et al. (67) reported on qualitative
esearch from top performers, indicating key characteristics
ssociated with success.
Despite growing interest in interventions and quality,
here is some disappointing evidence about the speed with
hich physicians adopt quality improvements. Audet et al.
68) reported on a national physician survey conducted in
003 and sponsored by the Commonwealth Fund that
valuated the use of quality improvement methods. Only
ne-third of respondents reported receiving feedback of
nformation about the quality of care that they provided.
oreover, only one-third reported engaging in redesign
fforts to improve the systems of care in their practice.
nterestingly, more than two-thirds thought that the public
hould probably not or definitely not have access to physi-
ian performance data.
Several studies addressed the impact of public reporting.
study by Hibbard et al. (69) found that public reporting
f hospital performance in Wisconsin was associated with
mprovements in the report areas, concluding that public
erformance information may stimulate improvements in
are. The news about public reporting, however, was not all
ositive. In a study of patient selection for PCI, Moscucci et
l. (70) found that in New York, which has public reporting,
here was a tendency to avoid high-risk cases compared with
ichigan, where public reporting is not practiced. Looking
orward, it will be important to consider both the positive
nd negative consequences of the implementation of poli-
ies for public reporting of performance.
ATIENT-CENTEREDNESS
everal studies support the integration of formal health
tatus assessments into clinical heart failure care. In an
nalysis of VAL-HeFT (Valsartan Heart Failure Trial),
ector et al. (71) assessed the correlates of quality of life in
atients with heart failure. Although dyspnea was strongly
ssociated with quality of life, traditional measures of heart
ailure severity, including ejection fraction, B-type natri-
retic peptide levels, jugular venous distension, peripheral
dema, systolic blood pressure, creatinine, and hemoglobin,
ere not strongly related to symptoms or quality of life.
imilarly, in a study of outpatients with heart failure, Luther
t al. (72) found no correlation between B-type natriuretic
eptide levels and health status. These studies show that
hysiologic measures of heart failure severity and health
tatus represent distinct domains, and measuring one does
ot necessarily provide meaningful information with respect
o the other. Additional evidence supports the prognostic
mportance of health status in heart failure independent of
hysiologic measures. Heidenreich et al. (73) found that in
n outpatient population with heart failure, poor health
tatus was a strong, independent predictor of death and
ospitalization after adjustment for clinical covariates,
-min walk distance, and B-type natriuretic peptide levels.
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November 7, 2006:1886–95 The Year in Epidemiology, Health Services Research, and Outcomes ResearchInvestigators also characterized health status outcomes in
ther patient populations. McCrindle et al. (74) assessed
ealth status in children after the Fontan procedure, finding
eficits in physical and psychological function that represent
otential targets for future intervention in this population.
leeper et al. (75) found that survivors of cardiogenic shock
reated with emergency revascularization achieved better
unctional status and quality of life than those receiving
nitial medical stabilization, and perhaps more surprisingly
chieved functional outcomes similar to those of historical
ontrols without shock undergoing elective intervention.
hese findings add further support to the use of an early
nterventional strategy in many patients with shock compli-
ating AMI despite persistently high mortality.
PIDEMIOLOGY
rogress in epidemiology during the year included several
tudies focused on the relationship between diet and car-
iovascular disease. In one of the most publicized reports of
he year, Howard et al. (76) presented the results of the
HI (Women’s Health Initiative) Randomized Controlled
ietary Modification Trial, which found that in postmeno-
ausal women, a dietary intervention of intensive behavioral
odification designed to reduce dietary fat intake and
ncrease consumption of vegetables, fruits, and grains over
ore than 8 years did not significantly reduce the risk of
oronary heart disease, stroke, or the composite of the two.
xperts are still trying to understand these findings that so
trikingly contradict conventional wisdom. In another con-
ribution from WHI, Howard et al. (77) reported that a
ow-fat diet was not associated with weight gain, contrary to
he concerns raised by advocates of low-carbohydrate diets.
ppel et al. (78), in another randomized trial, found that
lthough 3 diets low in saturated fats were effective at
owering estimated cardiovascular risk, diets substituting
rotein or monounsaturated fat for carbohydrate calories
xerted more favorable effects on blood pressure, lipid levels,
nd overall cardiovascular risk.
Two greatly anticipated randomized trials of the
annabinoid-1 receptor blocker rimonabant were published
RIO [Rimonabant in Obesity Lipids]-North America and
IO-Europe) (79,80). Both showed that in addition to a
alorie-restricted diet, treatment for 1 year with 20 mg daily
f rimonabant resulted in significantly greater weight loss
4.5 kg in both studies), greater decline in waist circum-
erence, and improvements in triglyceride and high-density
ipoprotein cholesterol levels. In RIO-North America, how-
ver, discontinuation of therapy after 1 year resulted in gain
f weight, and dropout rates in both studies in all treatment
rms were substantial, highlighting the persistent challenges
f sustaining any approach to weight loss (79).
Other studies further defined the relationship between
besity and cardiovascular events. The prospective Uppsala
ongitudinal Study of Adult Men found that measures ofnsulin resistance accounted for the relationship between Lbesity and the risk of heart failure, suggesting that insulin
esistance may be a central mechanism whereby obesity
ncreases heart failure risk (81). In a provocative analysis
rom the multinational case-control INTERHEART study,
usuf et al. (82) compared measures of obesity as markers of
isk. Body mass index (BMI), the current standard measure,
as not associated with increased risk of AMI after adjust-
ent for waist-to-hip ratio and other traditional risk factors.
n contrast, waist-to-hip ratio maintained an independent
raded relationship with obesity after multivariable adjust-
ent including BMI, suggesting that waist-to-hip ratio is a
linically more informative measure of obesity, at least with
espect to the risk of AMI.
Addressing the effects of dietary supplements, WHI
nvestigators found that 600 IU of vitamin E, although
ignificantly reducing cardiovascular death, did not reduce
he risk of cardiovascular events, cancer, or all-cause mor-
ality, further diminishing any remaining enthusiasm for
itamin E supplementation as a preventive measure (83).
nother trial with unexpected findings raised controversy
bout the proposed antiarrhythmic properties of omega-3
olyunsaturated fatty acids. In a randomized controlled trial
f patients with ICDs and recent ventricular tachyarrhyth-
ias, Raitt et al. (84) found that patients treated with 1.8
/day of fish oil did not have a lower risk of ventricular
achycardia (VT)/ventricular fibrillation (VF) than patients
eceiving placebo. More surprisingly, however, patients who
ualified for study enrollment because of VT had a signif-
cantly higher likelihood of receiving ICD therapy for
T/VF, and the overall risk of recurrent VT/VF was higher
n patients treated with fish oils (84).
Poor physical fitness also remains an important problem
s well as a potential opportunity for intervention. In
HANES, Carnethon et al. (85) found that more than
ne-third of U.S. adolescents had low fitness as defined by
heir maximal oxygen consumption (VO2max). Low fitness
evels were not surprisingly associated with cardiovascular
isk factors, including more obesity, higher blood pressure,
nd lower high-density lipoprotein cholesterol levels, pro-
iding perspective on the population impact of poor physical
tness. Another study provided some hope about effective
trategies to ameliorate the adverse consequences of physical
nactivity. In a randomized trial of patients with stable
oronary artery disease, Blumenthal et al. (86) assigned
atients to usual medical care, supervised aerobic exercise
35 min, 3 times weekly), or formal stress management
raining (1.5 h weekly) for 16 weeks. Patients in both
reatment arms had lower emotional distress and improved
hysiological markers of cardiovascular risk compared with
hose receiving standard therapy. The widespread dissemi-
ation of effective strategies, however, remains an important
hallenge.
The past year revealed greater insights into cardiovascular
hanges with aging. In a community cohort free of clinical
eart disease followed up for almost 8 years in the Baltimore
ongitudinal Study of Aging, investigators found that
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inear, but rather accelerated substantially with each decade
f age, particularly among men (87). Moreover, the decline
as seen across all quartiles of baseline reported physical
ctivity. In a cross-sectional study from Olmsted County,
ge was strongly associated with increased vascular stiffness,
n subjects both with and without established cardiovascular
isease, and the increase was significantly greater in women
88). The investigators speculate that this gender difference
ay explain the consistent preponderance of women in
opulations with heart failure and preserved left ventricular
ystolic function.
Several studies further examined traditional risk factors.
moking continues to be an important health threat. Ezzati
t al. (89) estimated that more than 1 in 10 of all cardio-
ascular deaths worldwide—or more than 1.6 million—in
he year 2000 were attributable to smoking. An analysis of
HANES data between 1960 and 2000 showed significant
eclines in the prevalence of hyperlipidemia (21%), hyper-
ension (18%), and smoking (12%) (90). Declines in hyper-
ipidemia prevalence were particularly marked in patients
ith high BMI, and overall changes in risk factor prevalence
ere associated with higher rates of use of lipid-lowering
nd antihypertensive medications, particularly among obese
ersons. Carroll et al. (91) examined contemporary trends in
erum lipid and lipoprotein levels in NHANES. They
ound that between the 1999 to 1994 and 1999 to 2002
urveys, there were significant declines in total and low-
ensity lipoprotein cholesterol but no significant change in
igh-density lipoprotein cholesterol, and a nonsignificant
ncrease in triglyceride levels. These encouraging changes,
ost prominent in men older than 50 years and women
lder than 60 years, were attributed to expanded use of
ipid-lowering medications. In a report using the Minnesota
eart Survey, Arnett et al. (92) found downward trends in
holesterol levels between 1980 and 2002 that were more
ronounced in middle-aged and older adults and correlated
ith higher treatment rates. However, substantial propor-
ions of the population in 2002 had hyperlipidemia, and the
ajority of these were unaware of their lipid levels. Thus,
espite recent gains in addressing traditional cardiovascular
isk factors, ongoing efforts to modify these factors remain
ikely to have important public health benefits.
Although risk factor profiles may be improving in some
ountries, they are emerging in others. In a cross-sectional
urvey in China, Gu et al. (93) reported that the age-
tandardized prevalence of metabolic syndrome among
dults age 35 to 70 years was 9.8% in men and 17.8% in
omen, and the prevalence of BMI of at least 25 kg/m2 was
6.9% in men and 31.1% in women. The prevalence was
igher in urban areas.
Risk models can be powerful tools for guiding decisions
bout the use of therapeutic interventions. Investigators
rom the CADILLAC (Controlled Abciximab and Device
nvestigation to Lower Late Angioplasty Complications)
rial developed and validated a risk score to predict mortalityfter primary PCI (94). In order of importance, left ven-
ricular ejection fraction, renal insufficiency, higher Killip
lass, poor postprocedure TIMI grade flow, older age,
nemia, and 3-vessel disease contributed to a risk score
redicting mortality with good discrimination at both 30
ays (c-index  0.81) and at 1 year (c-index  0.78). With
he New York state PCI database, Wu et al. (95) developed
risk score predicting in-hospital mortality for PCI. Patient
ge, gender, hemodynamic state, left ventricular ejection
raction, preprocedure AMI, peripheral artery disease, heart
ailure, renal failure, and left main disease all contributed to
risk score with excellent discrimination (c-index  0.89).
ritish investigators, using data from 7,311 patients in a
ulticenter trial, developed a risk score for predicting death,
MI, and stroke among stable outpatients with angina and
ormal left ventricular systolic function (96). The 16-
ariable score identified deciles of risk ranging from 4% to
5%. Euro Heart investigators developed a score predicting
utcomes in patients with stable angina (97). Six readily
vailable clinical factors (comorbidity, diabetes, shorter
ymptom duration, increasing severity of symptoms, ST-
egment depressions, or T-wave inversions on the electro-
ardiogram, and abnormal ventricular function) contributed
o a risk score with predicted outcomes ranging from about
% to 45% with reasonable discrimination (c-index 0.74).
ooking beyond the widely accepted 10-year time frame,
ramingham investigators developed an approach to predict
ifetime risk of incident cardiovascular disease for persons
ge 50 years. Not surprisingly, individuals without risk
actors had lower lifetime risks of developing cardiovascular
isease. The magnitude of the estimated differences in
edian survival between these 2 groups (11 years in men
nd 8 years in women) was particularly striking, again
mphasizing the potential impact of aggressive early risk
actor control (98).
ONCLUSIONS
he year witnessed a strong group of studies with direct
elevance to the prevention, diagnosis, and treatment of car-
iovascular disease. There is a growing interest and focus on
tudies that challenge conventional wisdom and produce in-
ights that can improve practice and policy. The translation of
his newly developed knowledge into practice and the gener-
tion of effective strategies for delivering discoveries into
atient care remain central challenges for future investigation.
ddress correspondence to: Dr. Harlan M. Krumholz, Yale
niversity School of Medicine, 333 Cedar Street, Room I-456
HM, PO Box 208088, New Haven, Connecticut 06520-8088.
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